earnings
AB
NASDAQ · ABOS
Acumen Pharmaceuticals, Inc.
Healthcare · Biotechnology
$3.18
Up+$0.09 (+2.91%)
Updated Sep 8, 2026, 11:36 AM
SID Score
6.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 190.2M
- P/E ratio
- -1.43
- Dividend yield
- 0.00%
- 52-week range
- $1.21 – $3.60
- Volume
- 315.43K
- Avg. volume
- 585.74K
Price performance
ABOS price history
1M range · 20 trading sessions · Daily adjusted prices
ABOS closed at $3.18 after 20 trading sessions, up 30.86% for the selected period.
- Last close
- $3.18
- Period change
- +30.86%
- Period low
- $2.43
- Period high
- $3.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $3.07 | $3.23 | $3.03 | $3.18 | 315.43K |
| Sep 3, 2026 | $3.13 | $3.165 | $3.05 | $3.09 | 453.41K |
| Sep 2, 2026 | $2.93 | $3.125 | $2.93 | $3.10 | 247.82K |
| Sep 1, 2026 | $2.80 | $2.95 | $2.80 | $2.92 | 188.97K |
| Aug 31, 2026 | $2.90 | $2.92 | $2.76 | $2.85 | 244.22K |
| Aug 28, 2026 | $3.02 | $3.02 | $2.885 | $2.92 | 305.77K |
| Aug 27, 2026 | $2.98 | $3.17 | $2.98 | $3.03 | 271.07K |
| Aug 26, 2026 | $3.09 | $3.09 | $2.915 | $2.99 | 235.09K |
| Aug 25, 2026 | $3.09 | $3.169 | $3.04 | $3.10 | 300.75K |
| Aug 24, 2026 | $3.17 | $3.17 | $3.04 | $3.075 | 275.96K |
| Aug 21, 2026 | $3.21 | $3.34 | $3.135 | $3.16 | 716.03K |
| Aug 20, 2026 | $3.12 | $3.245 | $3.01 | $3.19 | 599.75K |
| Aug 19, 2026 | $2.79 | $3.17 | $2.79 | $3.15 | 617.83K |
| Aug 18, 2026 | $2.66 | $2.79 | $2.6358 | $2.74 | 309.43K |
| Aug 17, 2026 | $2.66 | $2.74 | $2.62 | $2.66 | 412.85K |
| Aug 14, 2026 | $2.51 | $2.695 | $2.45 | $2.67 | 526.7K |
| Aug 13, 2026 | $2.50 | $2.55 | $2.39 | $2.55 | 449.31K |
| Aug 12, 2026 | $2.41 | $2.59 | $2.40 | $2.51 | 487.16K |
| Aug 11, 2026 | $2.44 | $2.50 | $2.42 | $2.47 | 204.69K |
| Aug 10, 2026 | $2.41 | $2.45 | $2.37 | $2.43 | 194.42K |
Latest ABOS news
The latest Smart Investors Daily articles mentioning ABOS.
Stock researchResearch & News · SEC Filings
Loading stock research…